Immunovant (IMVT) Prepaid Assets (2019 - 2026)
Immunovant's (IMVT) quarterly Prepaid Assets came in at $42.8 million in Q1 2026, down 16.45% YoY from $51.2 million in Q1 2025, and down 8.57% on a QoQ basis from $46.8 million in Q4 2025.
Immunovant (IMVT) Prepaid Assets (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Prepaid Assets data on file, last reported at $42.8 million in Q1 2026.
- Quarterly Prepaid Assets fell 16.45% year-over-year to $42.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 16.45% YoY) and the FY2026 annual result came in at $42.8 million, down 16.45% from the prior year.
- Prepaid Assets slipped to $42.8 million in Q1 2026, from $46.8 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $51.2 million in Q1 2025 to a low of $6.3 million in Q1 2022.
- A 5-year average of $29.7 million and a median of $26.6 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets dropped 18.96% — and 2023, when it jumped 330.45%.
- Tracing IMVT's Prepaid Assets over 5 years: stood at $21.1 million in 2022, then retreated by 10.9% to $18.8 million in 2023, then jumped by 89.43% to $35.6 million in 2024, then jumped by 31.26% to $46.8 million in 2025, then fell by 8.57% to $42.8 million in 2026.
- The last three Prepaid Assets figures came in at $42.8 million (Q1 2026), $46.8 million (Q4 2025), and $49.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.68 Mn |
| Mar 31, 2026 | 42.76 Mn |
| Dec 31, 2025 | 46.77 Mn |
| Sep 30, 2025 | 49.71 Mn |
| Jun 30, 2025 | 50.92 Mn |
| Mar 31, 2025 | 51.18 Mn |
| Dec 31, 2024 | 35.63 Mn |
| Sep 30, 2024 | 32.56 Mn |
| Jun 30, 2024 | 26.63 Mn |
| Mar 31, 2024 | 24.90 Mn |
| Dec 31, 2023 | 18.81 Mn |
| Sep 30, 2023 | 19.83 Mn |
| Jun 30, 2023 | 19.23 Mn |
| Mar 31, 2023 | 26.92 Mn |
| Dec 31, 2022 | 21.11 Mn |
| Sep 30, 2022 | 16.54 Mn |
| Jun 30, 2022 | 15.92 Mn |
| Mar 31, 2022 | 6.25 Mn |
| Dec 31, 2021 | 13.48 Mn |
| Sep 30, 2021 | 4.84 Mn |